The “rights” of precision drug development for Alzheimer’s disease

Abstract There is a high rate of failure in Alzheimer’s disease (AD) drug development with 99% of trials showing no drug-placebo difference. This low rate of success delays new treatments for patients and discourages investment in AD drug development. Studies across drug development programs in mult...

Full description

Bibliographic Details
Main Authors: Jeffrey Cummings, Howard H. Feldman, Philip Scheltens
Format: Article
Language:English
Published: BMC 2019-08-01
Series:Alzheimer’s Research & Therapy
Subjects:
Online Access:http://link.springer.com/article/10.1186/s13195-019-0529-5

Similar Items